News | Cardiac Imaging | May 10, 2024

Enlarged Lymph Nodes on Screening Mammograms Predict Cardiometabolic Disease, Cardiovascular Risk

A, Normal axillary lymph nodes measuring < 1.5 cm in 63-year-old woman with BM = 43.2. B, Fat-enlarged axillary node with large fatty hilum measuring 4.2 cm in 52-year-old woman with BMI = 45.8.

Variable LN morphology on screening mammograms in women with obesity due to ectopic fat deposition. A, Normal axillary lymph nodes measuring < 1.5 cm in 63-year-old woman with BM = 43.2. B, Fat-enlarged axillary node with large fatty hilum measuring 4.2 cm in 52-year-old woman with BMI = 45.8.


May 10, 2024 — According to the Summa Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting, fat-enlarged axillary nodes on screening mammograms can predict high cardiovascular disease (CVD) risk, Type 2 diabetes (T2DM), and hypertension (HTN).

“Incorporating fat-enlarged nodes into CVD risk models has the potential to improve CVD risk stratification without additional cost or additional testing,” said Jessica Rubino, MD, from Dartmouth Hitchcock Medical Center in Lebanon, NH. “Fat-enlarged axillary lymph nodes visualized on screening mammography may increase the ability to identify women who would benefit from CVD risk reduction strategies and more intensive risk assessment with coronary artery CT.”

Rubino et al. reviewed patients (women, 40–75 years) without known coronary artery disease who had a routine screening mammogram and cardiovascular risk factors available in the EMR within 1 year of the index mammogram (January 1, 2011–December 31, 2012). Evaluating major adverse cardiovascular events (MACE) within 10 years of the index mammogram, the researchers used clinical parameters at the time of the index mammogram to determine high estimated CVD risk via the pooled cohort equation (PCE) —defined by the American Heart Association as more than a 7.5% likelihood of MACE within 10 years. Two breast imagers evaluated screening mammograms to measure the length of the largest visible axillary LN in each breast in the mediolateral oblique view, analyzing the largest visible node for each patient. Logistic regression then examined associations between lymph node size, 10-year CVD risk, MACE, T2DM, HTN, low density lipoprotein (LDL), age, and BMI.

Ultimately, among 1,216 women included in this ARRS Annual Meeting Summa Cum Laude Scientific Poster, 907 (74.6%) had a visible axillary LN on the index mammogram, and 232 (19.1%) women had fat-enlarged nodes—defined as larger than 20 mm in length due to an expanded fatty hilum. Women with fat-enlarged nodes had a high risk of CVD defined by PCE (OR = 2.6, 95% CI 1.5–4.2), as well as a higher prevalence of T2DM (OR = 4, 95% CI 2.1–7.7) and HTN (OR = 2.5, 95% CI 1.6–4.0). Fat-enlarged nodes were also associated with a trend toward higher risk of MACE (OR = 1.7, 95% CI 0.9–3.1) and LDL (OR = 1.4, 95% CI 0.9–2.1).

“These results support further investigation of fat-enlarged lymph nodes,” Rubino added, “particularly with studies leveraging AI evaluation of mammographic fat-enlarged LNs and cardiometabolic disease.”

For more information: www.arrs.org

Find more ARRS24 conference coverage here


Related Content

News | Heart Failure

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care ...

Home October 28, 2025
Home
News | Heart Failure

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association ...

Home October 16, 2025
Home
News | Heart Failure

Sept. 24, 2025 — The Family Heart Foundation, a leading research and advocacy organization, has announced the online ...

Home September 24, 2025
Home
News | Heart Failure

Sept. 22, 2025 — The latest findings on heart failure (HF) published by the Heart Failure Society of America (HFSA) ...

Home September 22, 2025
Home
News | Heart Failure

Sept. 11, 2025 — Newswise — A new Mayo Clinic study finds that many heart attacks in people under 65 — especially women ...

Home September 15, 2025
Home
News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
Subscribe Now